TY - JOUR
T1 - Topical lipophilic epigallocatechin-3-gallate on herpes labialis
T2 - A phase II clinical trial of AverTeaX formula
AU - Zhao, Man
AU - Zheng, Rong
AU - Jiang, Jinyan
AU - Dickinson, Douglas
AU - Fu, Baiping
AU - Chu, Tin Chun
AU - Lee, Lee Hwang
AU - Pearl, Henna
AU - Hsu, Stephen
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/12
Y1 - 2015/12
N2 - Objective Previous in vitro and in vivo studies indicated that catechins from the tea plant (Camellia sinensis) have a therapeutic effect on herpes simplex virus infections. The aim of this study was to clinically evaluate a topical proprietary formulation containing lipophilic catechins (AverTeaX, Camellix, LLC, Evans, GA, USA) on recurrent herpes labialis. Study Design A double-blind, placebo-controlled, randomized trial with 40 participants, initially in two groups. Results Compared with the vehicle (100% glycerin USP, CVS Pharmacies, Inc., Woonsocket, RI, USA) group, AverTeaX applied topically six to eight times daily resulted in a significant reduction in clinical episode duration (median 4.5 days vs. 9 days; P =.003) and shortened blistering and ulceration stages within an episode from a median of 3 days to 1 day (P =.0003). Median quality-of-life scores, based on a multiquestion survey, showed significant differences between the groups with respect to duration of itching, from a median of 4 days to 1 day (P =.0021), and duration until symptom free, from a median of 8 days to 4 days (P =.0016). Significant differences were not found for median scores for itching, pain, burning, swelling, bleeding, and stress. Adverse effects were not reported. Conclusion AverTeaX formulation containing lipophilic catechins effectively inhibited herpes simplex labialis infection with clinical significance.
AB - Objective Previous in vitro and in vivo studies indicated that catechins from the tea plant (Camellia sinensis) have a therapeutic effect on herpes simplex virus infections. The aim of this study was to clinically evaluate a topical proprietary formulation containing lipophilic catechins (AverTeaX, Camellix, LLC, Evans, GA, USA) on recurrent herpes labialis. Study Design A double-blind, placebo-controlled, randomized trial with 40 participants, initially in two groups. Results Compared with the vehicle (100% glycerin USP, CVS Pharmacies, Inc., Woonsocket, RI, USA) group, AverTeaX applied topically six to eight times daily resulted in a significant reduction in clinical episode duration (median 4.5 days vs. 9 days; P =.003) and shortened blistering and ulceration stages within an episode from a median of 3 days to 1 day (P =.0003). Median quality-of-life scores, based on a multiquestion survey, showed significant differences between the groups with respect to duration of itching, from a median of 4 days to 1 day (P =.0021), and duration until symptom free, from a median of 8 days to 4 days (P =.0016). Significant differences were not found for median scores for itching, pain, burning, swelling, bleeding, and stress. Adverse effects were not reported. Conclusion AverTeaX formulation containing lipophilic catechins effectively inhibited herpes simplex labialis infection with clinical significance.
UR - http://www.scopus.com/inward/record.url?scp=84946544647&partnerID=8YFLogxK
U2 - 10.1016/j.oooo.2015.08.018
DO - 10.1016/j.oooo.2015.08.018
M3 - Article
C2 - 26548726
AN - SCOPUS:84946544647
SN - 2212-4403
VL - 120
SP - 717
EP - 724
JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
IS - 6
ER -